All In MedTech

510(k) device

Ceribell Monitor

Ceribell, Inc. · Reduced- Montage Standard Electroencephalograph (OMC, Class II) · First FDA decision Jun 30, 2026, newest Jun 30, 2026Epilepsy

Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

1

510(k) pathway

Device trials

5

Naming "Ceribell"

MAUDE reports

1

Brand "Ceribell", since 2015

PubMed studies

29

Mentioning "Ceribell"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Ceribell Monitor

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 1 of 1 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.

Clinical trials

Device studies on ClinicalTrials.gov that name "Ceribell", any status and sponsor, newest update first.

Open in Trial Radar
  • Ceribell Inc.Not on our public-company list

    NCT07449416 · 100 participants (planned) · Start Mar 15, 2026 · Primary completion Oct 2026

    Device: Ceribell Delirium Monitoring System · For: Delirium in the Intensive Care Unit

    Sites: Irvine, California; Pittsburgh, Pennsylvania

  • Ceribell Inc.Not on our public-company list

    NCT07485244 · 100 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 31, 2026

    Device: Ceribell EEG System · For: Delirium in the Intensive Care Unit

    Sites: Nashville, Tennessee

  • Ceribell Inc.Not on our public-company list

    NCT04962815 · 200 participants (planned) · Start Nov 10, 2021 · Primary completion Dec 31, 2025

    Device: Electroencephalogram (EEG) Test · For: Delirium

    Sites: Stanford, California; Naples, Florida; Iowa City, Iowa · 7 sites in all

2 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Ceribell", and for the whole product code for context.

This brand

1 reports: 1 malfunction, 0 injury, 0 death

Whole product code OMC

8 reports: 6 malfunction, 2 injury, 0 death

Newest reports for this brand

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "Ceribell"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code OMC.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.